StemCell Therapy

The transaction includes a significant proportion of non-UK overseas lives and will protect the Scheme from the risk of rising costs as a result of pensioner and dependent members living longer than expected.

CMS was appointed by the Scheme as legal counsel for this specific project following a competitive tender process and worked closely together with Hymans Robertson, the lead adviser to the Scheme. In a market first, the transaction optimised efficiencies for the Scheme through a combination of the following: allowing the Scheme to have exposure to Hannover Res credit risk; allowing the Scheme to benefit from Zurich retaining a substantive minority share of the longevity risk (in a product known as Enhanced Pass Through); and providing the Scheme the benefits of transacting with a UK regulated insurance company.The CMS team was led by Pensions Partner, James Parker, with assistance from Maria Rodia, Alex Tomlinson and Laura Clarke.Commenting on the transaction, James Parker said: We are delighted to have been able to assist the trustees to significantly reduce the longevity risk in their scheme and improve the security of members benefits. This is one of a series of high-profile transactions on which we have acted as transaction legal counsel this year, underlining CMS market-leading reputation in the pensions de-risking market.This transaction concludes a busy year for the CMS Pensions Team with highlight transactions including acting for Stanhope Pension Trust, trustee of the GEC 1972 Plan, on a 4.7 billion buy-out transaction with Rothesay Life the UKs biggest ever pension transfer deal.

Read the original:
Pensions - Articles - FTSE 100 pension scheme in ground breaking longevity swap - Actuarial Post

This entry was posted on December 22, 2019 at 1:49 pm and is filed under Longevity. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |